132 related articles for article (PubMed ID: 12962766)
1. Safety and efficacy of delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors over 55 years of age.
Gentil MA; Osuna A; Capdevila L; Rodriguez-Algarra G; Cantarell C; Pereira P; González-Molina M;
Transplant Proc; 2003 Aug; 35(5):1706-8. PubMed ID: 12962766
[TBL] [Abstract][Full Text] [Related]
2. Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age.
Osuna A; Gentil MA; Capdevila L; Cantarell C; Mazuecos A; Pereira P; Rodríguez-Algarra G; González-Molina M;
Transplant Proc; 2005 Apr; 37(3):1438-40. PubMed ID: 15866630
[TBL] [Abstract][Full Text] [Related]
3. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus.
González-Roncero FM; Gentil-Govantes MÁ; González-Molina M; Rivero M; Cantarell C; Alarcón A; Franco A; Sánchez-Plumed J; Lampreabe I; Lauzurica R; González E; Romero R; Ruiz-San Millán JC; Osuna A
Nefrologia; 2012 Jul; 32(4):446-54. PubMed ID: 22806279
[TBL] [Abstract][Full Text] [Related]
4. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
Gentil MA; Osuna A; Capdevilla L; Cantarell C; Pereira P; Mazuecos A; González Molina M
Nefrologia; 2008; 28(3):287-92. PubMed ID: 18590495
[TBL] [Abstract][Full Text] [Related]
5. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.
Gonwa TA; Mai ML; Smith LB; Levy MF; Goldstein RM; Klintmalm GB
Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin inhibitor-free immunosuppressive strategy in elderly recipients of renal allografts from deceased donors: 1-year results from a prospective single center trial.
Arbogast HP; Hoffmann JN; Illner WD; Hillebrand GF; Fischereder M; Jauch KW; Land W
Transplant Proc; 2009; 41(6):2529-32. PubMed ID: 19715968
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
Miller J; Mendez R; Pirsch JD; Jensik SC
Transplantation; 2000 Mar; 69(5):875-80. PubMed ID: 10755543
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
[TBL] [Abstract][Full Text] [Related]
10. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
[TBL] [Abstract][Full Text] [Related]
11. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
[TBL] [Abstract][Full Text] [Related]
12. Annual trends and triple therapy--1991-2000.
Nishikawa K; Terasaki PI
Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration.
Andrés A; Budde K; Clavien PA; Becker T; Kessler M; Pisarski P; Fornara P; Burmeister D; Hené RJ; Cassuto-Viguier E;
Transplantation; 2009 Nov; 88(9):1101-8. PubMed ID: 19898206
[TBL] [Abstract][Full Text] [Related]
14. Calcineurin-free protocols with basiliximab induction allow patients included in "old to old" programs achieve standard kidney transplant function.
Emparan C; Laukötter M; Wolters H; Dame C; Heidenreich S; Senninger N
Transplant Proc; 2003 Jun; 35(4):1326-7. PubMed ID: 12826150
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
Sánchez-Fructuoso AI; Prats D; Marques M; Ridao N; Conesa J; García Mena M; Torrente J; Barrientos A
Transplant Proc; 2003 Aug; 35(5):1689-90. PubMed ID: 12962759
[TBL] [Abstract][Full Text] [Related]
16. Deceased donor organ transplantation with expanded criteria donors: a single-center experience from India.
Goplani KR; Firoz A; Ramakrishana P; Shah PR; Gumber MR; Patel HV; Vanikar AV; Trivedi HL
Transplant Proc; 2010; 42(1):171-4. PubMed ID: 20172307
[TBL] [Abstract][Full Text] [Related]
17. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil.
Sola E; Alférez MJ; Cabello M; Burgos D; González Molina M
Transplant Proc; 2002 Aug; 34(5):1689-90. PubMed ID: 12176537
[No Abstract] [Full Text] [Related]
18. Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function.
González E; Gutiérrez E; Hernández Y; Roselló G; Gutiérrez MJ; Martínez EG; Manzanera MJ; García JA; Praga M; Morales JM; Andrés A
Transplant Proc; 2005 Nov; 37(9):3736-7. PubMed ID: 16386522
[TBL] [Abstract][Full Text] [Related]
19. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
[TBL] [Abstract][Full Text] [Related]
20. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco.
Vincenti F; Stock P
Transplant Proc; 2003 May; 35(3 Suppl):183S-186S. PubMed ID: 12742494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
